par Wechsler, M.E.;Akuthota, Praveen;Jayne, David R.W.David;Khoury, Paneez;Klion, Amy;Langford, Carol A;Merkel, Peter PA;Moosig, Frank;Specks, Ulrich;Cid, Maria MC;Luqmani, Raashid;Brown, Judith;Mallett, Stephen;Philipson, Richard;Yancey, Steve SW;Steinfeld, Jonathan;Weller, Peter F;Gleich, Gerald J;EGPA Mepolizumab Study Team, Florence;Roufosse,
; [et al.]
Référence The New England journal of medicine, 376, 20, page (1921-1932)
Publication Publié, 2017

Référence The New England journal of medicine, 376, 20, page (1921-1932)
Publication Publié, 2017
Article révisé par les pairs
Titre: |
|
Auteur: | Wechsler, M.E.; Akuthota, Praveen; Jayne, David R.W.David; Khoury, Paneez; Klion, Amy; Langford, Carol A; Merkel, Peter PA; Moosig, Frank; Specks, Ulrich; Cid, Maria MC; Luqmani, Raashid; Brown, Judith; Mallett, Stephen; Philipson, Richard; Yancey, Steve SW; Steinfeld, Jonathan; Weller, Peter F; Gleich, Gerald J; EGPA Mepolizumab Study Team, Florence; Roufosse, ; et al. |
Informations sur la publication: | The New England journal of medicine, 376, 20, page (1921-1932) |
Statut de publication: | Publié, 2017 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Antibodies, Monoclonal, Humanized -- adverse effects -- therapeutic use | |
Churg-Strauss Syndrome -- drug therapy -- immunology | |
Disease-Free Survival | |
Double-Blind Method | |
Drug Therapy, Combination | |
Eosinophils | |
Female | |
Glucocorticoids -- therapeutic use | |
Humans | |
Immunologic Factors -- adverse effects -- therapeutic use | |
Injections, Subcutaneous -- adverse effects | |
Intention to Treat Analysis | |
Leukocyte Count | |
Male | |
Middle Aged | |
Recurrence | |
Remission Induction | |
Langue: | Anglais |
Identificateurs: | urn:issn:0028-4793 |
info:doi/10.1056/NEJMoa1702079 | |
info:pmid/28514601 | |
PMC5548295 |